Invivyd's COVID Antibody PEMGARDA Retains Neutralization Power Against Key Variants, FDA Confirms
Portfolio Pulse from Benzinga Newsdesk
Invivyd, Inc. (NASDAQ:IVVD) announced that the FDA has updated the EUA Fact Sheet for their COVID antibody PEMGARDA, confirming its neutralization power against key variants. The update removes previous concerns about reduced susceptibility to certain variants.
October 01, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA's updated EUA Fact Sheet confirms that Invivyd's PEMGARDA retains neutralization power against key COVID variants, removing previous concerns about reduced susceptibility. This is a positive regulatory update for Invivyd.
The FDA's confirmation of PEMGARDA's efficacy against key variants is a significant regulatory endorsement, likely to boost investor confidence and positively impact Invivyd's stock price. The removal of previous concerns about reduced susceptibility further strengthens this position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100